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Background: Membranoproliferative glomerulonephritis (MPGN type I, II and III) was reclas-
siﬁed in 2013 as MPGN and C3 glomerulopathy (C3G) based on the complement system
activation mechanism.
Objectives: To evaluate whether C4d, a component of the classical pathway, could be a diag-
nostic tool in differentiating between MPGN and C3G.
Methods: We  conducted a retrospective study of 15 MPGN type I, II and III and 13 minimal
change disease (MCD) patients diagnosed between 2000 and 2012. C4d staining using the
peroxidase method was employed.
Results: Using the 2013 C3G consensus classiﬁcation, the 15 MPGN types I, II and III biopsies
were re-classiﬁed as MPGN (8) and C3G (7). Following C4d staining, of the 8 biopsies diagnosed
as  MPGN, 4 had classical pathway involvement [C1q (+), C3 (+), C4d (+)]; two had lectin
pathway involvement [C1q (−), C3 (+), C4d (+)]; and, two were reclassiﬁed as C3G because
the  absence of C4d and C1q suggested the presence of the alternative pathway [C1q (−),
C3 (+), C4d (−)]. Three of the seven C3G biopsies presented classical pathway involvement
and were reclassiﬁed as MPGN. The alternative pathway was present in one of the other
4  biopsies considered to be C3G. Two C3G biopsies involved the lectin pathway and the one
case  of dense deposit disease had lectin pathway involvement.
Conclusions: C4d staining may help to differentiate between MPGN and C3G. In addition, the
lectin pathway could play a role in the pathogenesis of these glomerulopathies.©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Please cite this article in press as: Gupta N, et al. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis. Nefrologia.
2016. http://dx.doi.org/10.1016/j.nefro.2016.05.011
∗ Corresponding author.
E-mail address: peacock7@uﬂ.edu (N. Gupta).
ttp://dx.doi.org/10.1016/j.nefro.2016.05.011
211-6995/© 2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the CC
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Uso  de  C4d  como  herramienta  diagnóstica  para  clasiﬁcar
la  glomerulonefritis  membranoproliferativa
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r  e  s  u  m  e  n
Antecedentes: La glomerulonefritis membranoproliferativa (GnMP, tipo I, II y III) fue reclasi-
ﬁcada en 2013 como GnMP y glomerulopatía C3 (GC3) en base al mecanismo que activa el
sistema del complemento.
Objetivos: Evaluar si C4d, componente de la vía clásica, puede diferenciar GnMP y GC3.
Métodos: Estudio retrospectivo incluyendo 15 pacientes con GnMP (tipo I, II y III) y 13 con
enfermedad de cambios mínimos (CM) diagnosticados entre 2000 y 2012. Realizamos tinción
renal con C4d mediante el método de la peroxidasa.
Resultados: En base a la deﬁnición de GC3 consensuada en 2013, las 15 biopsias diagnos-
ticadas como GnMP se reclasiﬁcaron como GnMP y GC3 en 8 y 7 casos respectivamente.
Tras  la tinción de C4d; de las 8 biopsias diagnosticadas como GnMP, 4 mostraron activación
de  la vía clásica [C1q (+), C3 (+), C4d (+)], 2 activación de la vía de las lectinas (VL) [C1q (-),
C3  (+), C4d (+)]; y 2 fueron reclasiﬁcadas como GC3 dada la ausencia de C4d y C1q sugiriendo
participación de la vía alternativa [C1q (-), C3 (+), C4d (-)]. Tres de 7 biopsias diagnosti-
cadas de GC3fueron reclasiﬁcadas como GnMP debido a las presencia de activación de la vía
clásica. La vía alternativa estuvo presente in 1 de las otras 4 biopsias consideradas GC3. VL
estuvo activada en 2 de biopsias diagnosticadas de GC3 y en el único caso de enfermedad
de  depósitos densos.
Conclusiones: C4d puede ayudar a diferenciar GnMP y GC3. La VL podría jugar un papel en la
patogenia de estas glomerulopatías.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
Membranoproliferative glomerulonephritis is a pattern of
glomerular injury that results from several distinct etiologies
of glomerular disease. Since the 1970s, the initial classiﬁcation
for MPGN has included MPGN type I, II (dense deposit disease
or DDD), and III based on light microscopy (LM), immunoﬂuo-
rescence (IF), and electron microscopy (EM).1–5
Membranoproliferative glomerulonephritis is character-
ized on LM by mesangial and endothelial hypercellularity,
increased mesangial matrix, and thickening of the glomeru-
lar capillary wall, often giving it an accentuated lobular
appearance. By IF, there is granular capillary wall deposi-
tion of (IgG and/or IgM) with complement C3 in MPGN type
I. Immunoglobulins are usually absent in the glomeruli of
DDD and MPGN type III. On EM,  electron dense deposits
are usually located in the subendothelial region in MPGN
type I, intramembranous location in DDD, and subendothe-
lial, intramembranous and subepithelial areas in MPGN type
III. DDD is deﬁned by its characteristic osmiophilic intramem-
branous deposits on EM and predominance of complement C3
on IF.
The ﬁrst C3 Glomerulopathy6 consensus introduced a
classiﬁcation for membranoproliferative glomerulonephritis
based on the pathogenesis involving the complement cas-
cade. MPGN associated with deposition of immunoglobulins
and complement (previously called MPGN type I or III) isPlease cite this article in press as: Gupta N, et al. Use of C4d as a diagnostic t
2016. http://dx.doi.org/10.1016/j.nefro.2016.05.011
believed to be immune complex mediated and; therefore,
activates the classical complement pathway. Cases with pre-
dominant C3 deposition with little or no immunoglobulinby-nc-nd/4.0/).
staining implies complement activation via the alternative
pathway and are designated C3 glomerulopathy (C3G).7–18
Using a strict approach, C3G has been deﬁned as “dominant C3
of ≥2 orders of magnitude of intensity by IF greater than any
other immune reactant”.14 C3G is subdivided into DDD and
C3 glomerulonephritis (C3GN). DDD continues to be charac-
terized by dark, osmophilic intramembranous deposits on EM
and predominance of complement C3.19 C3GN now incorpo-
rates some of those that were previously designated as MPGN
types I and III.
As previously mentioned, the pathogenesis of MPGN and
C3G involves the activation of the classical and alternative
pathways, respectively. The complement system consists of
three pathways: classical, lectin, and alternative. All three
pathways end up activating C3, which then progresses to form
the membrane attack complex (C5-C9) to induce localized cel-
lular injury and inﬂammation.20,21 The classical pathway is
initiated by immunoglobulins and involves the early comple-
ment components of C1q, C2 and C4. The lectin pathway is
initiated by mannose-binding lectin or ﬁcolins which activate
C2 and C4. No C1q is involved in the lectin pathway. The clas-
sical and lectin pathways end result is the formation of C3
convertase (C4b2b). The alternative pathway has a sponta-
neous activation of C3 by hydrolysis of its thioester bond that
initiates the complement cascade and does not involve the
early components of the cascade (C1q, C2 and C4). As the result
of the cleavage of C4 in the lectin and classical pathways, C4d
is formed. Since C4d has an internal thioester bond, it hasool to classify membranoproliferative glomerulonephritis. Nefrologia.
the ability to form a covalent bond to cell surfaces. With C4d
being tightly anchored to the tissue site, it is an ideal marker
of inﬂammation or injury.22
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Since no signiﬁcant C4b or its metabolite C4d is formed
n the alternative pathway, we have used C4d immunohisto-
hemistry as a method to screen for pathways of complement
ctivation involved in the pathogenesis. Positive glomerular
apillary wall immunoreactivity for C4d would favor involve-
ent of the classical complement pathway and negative C4d
taining would favor involvement of the alternative pathway
aterials  and  methods
atient  selection
his retrospective study included both adult and pediatric
atients who  had the 1970 original diagnosis of MPGN type I, II,
II. Minimal change disease (MCD) served as a comparison con-
rol group. Patients were identiﬁed from the Informatics for
ntegrating Biology and the Bedside Query & Analysis Tool soft-
are based on the ICD-9 codes. ICD-9 codes 581.2, 582.2, and
83.2 were used to identify patients with MPGN. ICD-9 code
81.3 was used to identify patients with MCD.  The patients
ere seen at the University of Florida (UF) from January 2000
o December 2012. Patients with de novo and recurrent MPGN
ype I, II, III in renal transplant were also included, along with
 heterogeneous mixture of primary and secondary causes of
PGN (atypical hemolytic uremic syndrome, cryoglobuline-
ia, hepatitis C, and monoclonal gammopathy of unknown
igniﬁcance). Pertinent clinical data were recorded. The study
as approved by the Institutional Review Board ofﬁce at UF.
4d  Immunohistochemistry
ormalin-ﬁxed parafﬁn-embedded tissue sections were
tained using the rabbit anti-human C4d polyclonal anti-
ody (American Research Products, Inc, Waltham, MA,
atalog number 12-5000) via an immunoperoxidase method
stablished at our institution (Procedure: XT ultraView DAB
3).
Four micron thick parafﬁn slides were placed on plus slides,
ried for 2 h in a 60 ◦C oven and placed on the Ventana Bench-
ark automated immunostainer where they were dewaxed
nd heat induced epitope retrieval was performed with Ven-
ana’s CC1 retrieval solution for 30 min  at 95–100 ◦C. Primary
ntibody, anti-human C4D (1:20 dilution) was applied to sec-
ions at 37 ◦C for 32 min. Immunoreactivity was visualized
y using the Ultra View DAB detection kit (Ventana Medical
ystems, Inc. Tucson, AZ). Slides were counterstained with
ematoxylin, dehydrated, cleared, and mounted with perma-
ent mounting media.
Glomerular staining results for C1q and C3, performed by
tandard immunoﬂuorescence methodology, were collected
uring the review of the pathology reports.
athology  review
he histological sections were reviewed by all authors whoPlease cite this article in press as: Gupta N, et al. Use of C4d as a diagnostic to
2016. http://dx.doi.org/10.1016/j.nefro.2016.05.011
ere blinded to any identiﬁers during the reviews. To include
atients in this study, any number of glomeruli was accepted.
irst, the cases were categorized based on their original
athology report and subsequently classiﬁed based on the new x(x x):xxx–xxx 3
2013 C3G consensus report in which glomerular C3 staining
of at least >2 orders of magnitude of intensity by IF greater
than any other immune reactant was considered dominant
and indicative of C3G. DDD was characterized by its clas-
sic osmophilic intramembranous deposits on EM.  Finally, the
cases were sorted based on the C4d immunoreactivity results.
Scoring  of  slides
Only peripheral capillary loop staining for C4d was scored. To
score glomeruli as positive or negative staining, we  relied on
both the intensity and distribution of the immunoreactivity.
Intensity of C4d staining in the capillary loop was based on a
scale of 0 to 3+ staining. The distribution was either global
or segmental capillary loop staining. Glomeruli with global
0 to trace C4d staining were considered negative. Glomeruli
regardless of intensity with less than 15% segmental C4d
staining were also considered negative. Sclerotic, scarred, or
collapsed glomerulus, whether global or segmental which may
have IgM, C3 and/or C1q trapping, were not scored. Global cap-
illary (GC) loop staining had ≥50% of the glomerulus staining
with greater than 1+ intensity. Segmental capillary (SC) loop
staining had <50% of the glomerulus staining with greater
than 1+ intensity. Diffuse C4d staining was deﬁned as ≥50%
of the total glomeruli staining, and focal C4d staining was
deﬁned as <50% of the total glomeruli staining. Any dis-
agreement on biopsy classiﬁcation or intensity staining was
resolved by reviewing the pathology slides as a group and
agreeing with the majority.
Statistics
Statistics were performed using Mann–Whitney and chi-
squared tests.
Results
After the initial screening, 23 MCD and 32 MPGN type I, II, III
patients were selected. Of the MCD patients, those with no
reported IF (n = 4) were excluded. Of the MPGN patients, those
with no reported IF (n = 7), EM (n = 2), or neither IF and EM (n = 2)
were excluded. After refacing the parafﬁn block of the original
biopsy samples, 6 MPGN and 6 MCD patients had no glomeruli
for C4d immunohistochemical (IHC) staining. Therefore, our
study included a ﬁnal sample of 13 MCD,  14 MPGN (type I and
III) and 1 DDD patient.
Patients  and  laboratory  ﬁndings  (Table  1)
The MCD  patients were 3–25 years old (average = 11.5 years),
with 3 males and 10 females. The MPGN type I, II, III patients
were 11–66 years old (average = 36.5 years), with 5 males and
10 females.
The etiologies of MPGN were: idiopathic MPGN (n = 8), de
novo MGPN in transplant (n = 2), atypical hemolytic uremicol to classify membranoproliferative glomerulonephritis. Nefrologia.
syndrome (n = 1), Hepatitis C (n = 2), cryoglobulinemia (n = 1),
and cryoglobulinemia with MGUS (monoclonal gammopathy
of unknown signiﬁcance) (n = 1). The DDD patient tested pos-
itive for C3 nephritic factor and had recurrence of DDD two
ARTICLE IN PRESSNEFRO-224; No. of Pages 9
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Table 1 – Pathological and clinical data of patients.
ID Age/sex C3
(90–180 mg/dL)
C4
(15–46 mg/dL)
Pr/Cr ratio at
biopsy
Serum
creatinine at
biopsy
Etiology
1 11/F 116 30 10.9 0.8 Idiopathic
2 13/M 112 12 2.71 0.4 Idiopathic
3 16/F 15 24 5.7 0.96 Idiopathic
4 21/M 145 54 0.76 4.5 Idiopathic
Recurrent MPGN 4 years after 1st DDKT
5 43/M 135 28 11.76 4.2 De  novo MPGN 7 years after 2nd DDKT
6 29/F 115 29 3.43 2.78  De novo MPGN 4 months after 1st DDKT
7 17/M 44 20 1.05 1.31 aHUS (low Factor H level)
8 16/F 129 29 5.06 0.8 Idiopathic
9 59/F 51 <3 3.6 0.8 Cryoglobulinemia Glomerulonephritis
10 16/F 33 20 1.63 0.85 Idiopathic (+ C3Nef)
Recurrence of DDD 1 year after 1st DDKT
11 62/F 132 25 0.15 1.54 Idiopathic
Recurrent MPGN 2 years after 1st DDKT
12 64/M 42 25 5.36 2.77 Idiopathic
13 56/F 65 <3 1.03 2.22 Hepatitis C
14 66/F 59 <2 4.9 4.48 Cryoglobulinemia Glomerulonephritis; MGUS
15 59/F 28 <2 3.45 1.31 Hepatitis C
sed d
US, mNote:  MPGN, membranoproliferative glomerulonephritis; DDKT, decea
atypical hemolytic uremic syndrome; C3Nef, C3 nephritic factor; MG
years after the transplant. Only 1 of 5 (ID 4) renal transplant
biopsies reported mild allograft rejection with C4d staining.
C4d  Immunohistochemistry
MCD:  glomerular  staining  with  C4d  immunohistochemistry
Twelve biopsies had negative C4d glomerular capillary loop
staining. Only one biopsy had diffuse glomerular staining. Of
the 17 glomeruli available in this biopsy, 8 had segmental
capillary loop (SC) staining of less than 25% per glomeru-
lus, 1 glomeruli had global capillary loop (GC) staining, and
8 glomeruli had negative staining. Overall, there were a total
of 127 glomeruli in the MCD  biopsy cases, of which only
9 glomeruli stained with C4d (7%).
MPGN  and  C3G:  glomerular  staining  with  C4d
immunohistochemistry
Twelve biopsies (80%) had C4d glomerular staining (see
Table 2). Eleven of 12 biopsies (92%) had diffuse glomerular GC
staining including the DDD case. Two biopsies (ID 3 and 12) had
diffuse GC staining with some focal glomerular C4d negativity
(1 of 13 glomeruli and 3 of 13 glomeruli, respectively). One case
(ID 7) had focal segmental distribution with 2 of 7 glomeruli
showing SC staining and 5 of 7 glomeruli negative. Three cases
(ID 13, 14, 15) had completely negative glomerular capillary
loop staining.
Overall, 63 of 113 glomeruli in the MPGN and C3G groups
stained with C4d (56%). Between the MPGN and C3G groups,
the MPGN had more  glomerular staining (88% vs. 32%). The dif-Please cite this article in press as: Gupta N, et al. Use of C4d as a diagnostic t
2016. http://dx.doi.org/10.1016/j.nefro.2016.05.011
ference in C4d staining between MCD,  MPGN and C3G was also
statistically signiﬁcant (p < 0.001). The intensity of the staining
was variable from 1+ to 3+, with a predominance of 3+ staining
when compared to the MCD  biopsies.onor kidney transplant; LRKT, living related kidney transplant; aHUS,
onoclonal gammopathy of unknown signiﬁcance.
MPGN:  classiﬁcation  using  the  C3G  consensus  criteria
The 15 MPGN type I, II, III cases based on the original pathology
report were reclassiﬁed according to the C3G consensus crite-
ria after reviewing the C3 IF results (see Table 2). Six patients
were designated as C3GN and eight patients were designated
as MPGN. One patient despite the lack of dominant C3 IF pat-
tern was classiﬁed as DDD because she had a characteristic
electron-dense intramembranous appearance on EM.
MPGN:  classiﬁcation  using  C4d  and  C1q  for  complement
pathway  identiﬁcation
We deﬁne the complement pathway activation using the com-
bined results of the C4d and C1q stains (see Tables 3 and 4;
Fig. 1). If C1q and C4d were positive, the classical pathway
was suggested; if both Clq and C4d were negative, the alterna-
tive pathway was suggested; if C1q was negative and C4d was
positive, then the lectin pathway was suggested.
Of the 8 biopsies diagnosed with MPGN using the con-
sensus criteria, 4 had classical pathway involvement due to
glomerular staining with C1q (+), C3 (+), C4d (+); and, two biop-
sies had lectin pathway involvement due to C1q (−), C3 (+), C4d
(+) pattern. Two biopsies in this group were reclassiﬁed as C3G
because the absence of C4d and C1q suggested the presence
of the alternative pathway complement.
Three of the six C3G biopsies had C4d and C1q positive
staining, suggesting classical pathway and were reclassiﬁed
as MPGN. The alternative pathway (C1q (−), C3 (+), C4d (−))
was present in one of the other 3 C3G biopsies. In the other
two, it seems that the lectin pathway was involved (C1q (−),
C3 (+), C4d (+)).ool to classify membranoproliferative glomerulonephritis. Nefrologia.
Discussion
Since the 1970s and until recently, MPGN types I, II and
III have been deﬁned according to their characteristic
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Table 2 – C4d Immunohistochemistry stain in MGPN and C3G.
ID Number of
glomeruli
C4d stain
(number of
glomeruli)
Immunoﬂuorescence on pathology report Electron microscopy on pathology
report
Diagnosis
on
pathology
report
Diagnosis
based  on
C3G con-
sensus
Diagnosis
after C4d
stain
Complement
pathway
C3 C1q IgM IgG Sub-
endo
Sub-
epi
Intra-
memb
Mes-
angial
1 1 GC = 3+ (1) 3+ 1+ 1+ 1+ − + − − MGPN III C3GN MPGN Classical
2 4 GC = 3+ (4) 3+ 1+ 1+ 1+ + − + + MPGN I C3GN MPGN Classical
3 13 GC = 2-3+ (12)
NS= (1)
1+ 1+ 1+ 1+ + + − − MPGN I MPGN MPGN Classical
4 4 GC = 2-3+ (4) 1+ 1+ 1+ 1+ + − − + Recurrent
MPGN I
MPGN MPGN Classical
5 4 GC = 3+ (4) 3+ 2+ 3+ 1+ + − − − De novo
MPGN I
MPGN MPGN Classical
6 4 GC = 2-3+ (4) 2+ 1+ 2-3+ 1-2+ + − − + De novo
MPGN I
MPGN MPGN Classical
7 7 SC = 2-3+ (2)
NS= (5)
3+ 1+ 1+ – + + − − MPGN I C3GN MPGN Classical
8 8 GC = 2-3+ (8) 2+ – – 2-3+ + + + + MPGN I MPGN MPGN Lectin
9 3 GC = 3+ (2)
SC = 2-3+ (1)
1+  – 1+ Trace + − − − MPGN I MPGN MPGN Lectin
10 7 GC = 2-3+ (7) 1+ – 1+ – − − + − Recurrent
DDD
DDD DDD Lectin
11 4 GC = 2-3+ (4) 3+ – – Trace + − − + Recurrent
MPGN I
C3GN C3GN Lectin
12 13 GC = 1-2+ (10)
NS= (3)
1+ – – – + + + − MPGN I C3GN C3GN Lectin
13 8 NS= (8) 1+ – 3+ – + + − − MPGN I MPGN C3GN Alternative
14 7 NS = (7) 1-2+ – 1-2+ 1+ + − − − MPGN I MPGN C3GN Alternative
15 26 NS = (26) 2-3+ – 1-2+ – + − − − MPGN I C3GN C3GN Alternative
Note:  Subendo, subendothelial deposits; Subepi, subepithelial deposits; Intramemb, intramembranous deposits.
GC,global capillary loop (>50% glomerular stain); SC,segmental capillary loop (<50% glomerular stain); NS,no glomerular stain;; MPGN, membranoproliferative glomerulonephritis); C3GN, C3
glomerulonephritis; DDD, dense deposit disease.
Please cite this article in press as: Gupta N, et al. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis. Nefrologia.
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MCD (Control)  MPGN (Classical)  MPGN (Lectin) 
C4d 
stain a b c
IF  Negative C1q 
 dd
Positive C1q (1+) 
e 
Negative C1q 
f 
Negative C3 
g
Positive C3 (3+) 
 h
Positive C3 (3+) 
i
EM j k l
DDD (Lectin) C3GN (Lectin) C3GN (Alternative) 
C4d 
stain m n o
IF  Negative C1q 
p
Negative C1q 
q
Negative C1q 
r
Positive C3 (1+) 
s
Positive C3 (1+) 
t
Positive C3 (2-3+) 
u
EM v w x 
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Fig. 1 – Biopsy classiﬁcation involving the complement cascade based on C4d stain, IF, and EM.  The light microscopy (not
shown) that is consistent with a membranoproliferative pattern along with immunoﬂuorescence (IF) and electron
microscopy (EM) pattern deﬁnes MPGN and C3G. By using C4d immunohistochemistry, C1q and C3 on IF, the involvement of
a particular complement pathway can be suggested.
Minimal change disease (MCD) biopsy serves as a control. There is no detection of glomerular capillary loop C4d stain (a), no
presence of glomerular C1q (d) or C3 (g) by IF, and on EM (j) there is podocyte effacement with no electron dense deposits.
MPGN (classical) phenotype shows predominant global capillary loop C4d stain (b), positive glomerular C1q (e) and positive
C3 (h) on IF. The EM (k) shows presence of subendothelial electron dense deposits.
MPGN (lectin) phenotype shows predominance of global capillary loop and mesangial C4d staining (c), negative glomerular
C1q (f) and positive glomerular C3 (i) on IF. The EM (l) here shows presence of large subendothelial and mesangial deposits.
DDD (lectin) phenotype shows dramatic linear global capillary loop C4d stain (m), negative glomerular C1q (p), and positive
glomerular C3 (s) on IF. The EM (v) here shows the characteristic dark, linear osmophilic intramembranous electron dense
deposits.
C3GN (lectin) phenotype shows predominance of global capillary loop C4d stain (n), negative glomerular C1q (q), and positive
glomerular C3 (t) on IF. The EM (w)  here shows subendothelial deposits.
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athological features observed on LM,  IF and EM. However,
any  of the heterogeneous lesions of MPGN “could not be
atisfactorily placed within existing pathological descriptions
ased on morphology.6” To resolve this confusion, the ﬁrst C3
lomerulopathy in 2012 attempted to describe MPGN based on
ts pathogenesis, where MPGN involves the classical comple-
ent pathway and C3G involves the alternative complement
athway activation. Based on the above proposed pathogene-
is of MPGN and C3G, we  introduced glomerular C4d and C1q
mmunohistochemistry (IHC) stains as an approach to differ-
ntiate between MPGN entities. Neither the C4d stain nor the
1q stains, which are involved in the early part of the comple-
ent cascade, were included in the recent C3G consensus.
The C4d technique can be performed by either parafﬁn-IHC
r frozen-IF methods.23 Both techniques have reports of intra-
nd inter-observer variability. We  use the parafﬁn-IHC method
or two main reasons. One it does not require a frozen sam-
le. Second, the IF method, although more  sensitive and rapid
ith a lower background noise, is not a permanent staining
nd does not work on parafﬁn sections.24 The largely nega-
ive C4d IHC staining in the glomerular capillary wall of MCD
ases and the stark C4d staining difference between C3GN andPlease cite this article in press as: Gupta N, et al. Use of C4d as a diagnostic to
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PGN indicated that our C4d technique was appropriate and
ccurate.
Table 3 – Suggested complement pathway based on the
early complement component proﬁle.
C1q C4d C3 Complement pathway
+ + + Classical
− + + Lectin
− − + Alternative
Table 4 – Number of glomeruli involved in each speciﬁc
complement pathway.
Classical Lectin Alternative Unknowna
MPGN 31 11 0 6
C3G 0 21 44 0
a It is labeled unknown because there was presence of C1q and C3
without C4d (i.e., ID 3 and ID 7). loop C4d stain, negative C1q, and positive C3. The EM
In our study, we  observed that C4d IHC showed intense, dif-
fuse >2+ glomerular capillary wall staining in majority of the
MPGN glomeruli when compared to the predominant nega-
tive staining of C4d in the C3G glomeruli (p < 0.0001). Recently,
a new entity of C4 DDD was reported where extensive work-
up revealed renal deposits of C4d with “absence of alternative
pathway activation”.25 Similar ﬁnding in our DDD patient
supports that a pathway besides the presumed alternative
pathway, such as the lectin pathway or C-reactive protein, may
be involved in the pathogenesis. Although C-reactive protein
can activate C4, it generally does not lead to full complement
pathway activation.23
A recent study by Sethi et al.26 reported a high sensitivity
and speciﬁcity for negative C4d (93% and 100%, respectively)
and negative C1q (97% and 63%, respectively) in C3G versus
immune complex-mediated GN (MPGN, SLE, IgA, membra-
nous, ﬁbrillary GN). Thus, Sethi’s and our studies suggest that
staining for C4d is valuable in differentiating C3G from MPGN.
Based on our complement composite proﬁle of C1q, C3 and
C4 staining, the presence of both C1q and C4d made a stronger
case for the involvement of the classical pathway in seven
biopsies, all of which were classiﬁed as MPGN. The absence
of C1q and presence of C4d was suggestive of the lectin path-
way in ﬁve biopsies, two were classiﬁed as MPGN and three as
C3G. The absence of both C1q and C4d was more  suggestive
of the alternative pathway in three biopsies, all of which were
C3G. Similar to Sethi et al.26 our results also emphasize that
the lectin pathway may be common to both MPGN and C3G.
These results indicate that the pathogenesis in MPGN and
C3G is more  complex than previously thought, and that the
pathogenesis proposed by C3G consensus may warrant fur-
ther investigation. In fact, this study highlights the importance
of a more  prospective, comprehensive and larger study that
includes further complement proﬁle testing and conﬁrm the
presence of lectin pathway to formally elucidate the patho-
genesis of MPGN and C3G.
It is also important to note that, in this study, the serumol to classify membranoproliferative glomerulonephritis. Nefrologia.
C4 level was variable among the MPGN and C3G groups. C4
was low in two of nine MPGN patients and in three of six
C3G patients. Of the three C3GN patients, two had Hepatitis
C and one had MGUS/cryoglobulinemia glomerulonephritis.
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It is believed that C4 is low in such patients due to persis-
tent antigenemia and/or antigen-antibody immune complex
deposition in the glomerulus.27-31 However, in the absence of
glomerular C4d staining and absent cryoglobulins on renal
biopsy, the low serum C4 may be related to extra-renal sys-
temic consumption of the complements and not due to direct
glomerular deposits. Another possibility for the low comple-
ment is hyposynthesis in the liver.32 Hence, the low serum C4
level may falsely reassure one of the classical pathway acti-
vation. It is also suggested that a primary trigger can lead to
unregulated alternative pathway activation that overwhelms
the compensatory regulatory mechanism, triggering glomeru-
lar deposition of complement factors.21 This idea is supported
by case ID 7, where the staining proﬁle suggests classical
pathway despite having low Factor H levels. Since this is a ret-
rospective study, the above hypothesis could not be validated
since no genetic testing involving the alternative pathway had
been performed to document a mutation that could have been
precipitated by a primary infection.
As a retrospective study, there are inherent limitations. The
limitations include small sample size, number of glomeruli per
biopsy, lack of molecular testing of the lectin pathway, and
lack of conﬁrmatory genetic testing of the alternative path-
way. However, we  did see distinct differences between the
C4d staining among the MCD,  MPGN and C3G groups, which
indicates that the staining method in itself was appropriate
and useful. With samples that had fewer than six glomeruli
per biopsy, sampling error and misinterpretation could be
confounders. However, this often mimics realistic situations
where inadequate biopsy specimens are obtained and the
diagnosis is rendered on relatively small number of glomeruli.
Due to tissue sample quantity, additional sections for further
complement components involving the lectin pathway could
not be performed. We  also understand that the study has a
small mixture of heterogeneous patients (both primary and
secondary MPGN). However, whether the disease process is
primary or secondary, the utility of C4d stain in suggesting
a speciﬁc complement pathway activation is still of beneﬁt,
especially when it is interpreted as part of the complement
proﬁle composite.
In summary, MPGN and C3G are complex disease pro-
cesses and further research is necessary to unravel their
pathogenesis. Due to the novelty of C3G diagnosis, our center
has only recently started performing a more  comprehen-
sive genetic work-up on selected patients. Investigations for
factor deﬁciency, factor auto-antibodies, and genetic comple-
ment mutations are needed but are costly. Undoubtedly, mass
spectrometry-based proteomic approaches may also be help-
ful, but limited in access.33 Thus, we believe that this relatively
simple and widely available C4d staining, when combined
with other complement stains (C1q and C3), could provide
better understanding of MPGN pathogenesis and facilitate
identiﬁcation of C3G more  easily.
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Importance  of  article
MPGN is a histopathological diagnosis that denotes a pat-
tern of glomerular injury seen on light microscopy. In the
past, MPGN was sub-classiﬁed into type I, II and III by
immunoﬂuorescence and electron microscopy. The ﬁrst C3
Glomerulopathy consensus published in 2013 attempted to
classify MPGN based on the pathogenesis involving the com-
plement cascade. MPGN type I is believed to be due to immune
complex mediated glomerular injury whereas C3G is believed
to be due to the dysregulation of the alternative pathway. In
this study, we deﬁne the complement cascade involvement by
using the glomerular C4d and C1q proﬁles. These results indi-
cate that the pathogenesis in MPGN and C3G is more  complex
than previously thought, and that the pathogenesis proposed
by C3G consensus may warrant further investigation. In addi-
tion, for the ﬁrst time, it is suggested that the lectin pathway
may also be involved in the pathogenesis of MPGN in some
patients.
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